Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Current Report · Items 2.02, 9.01 · 8-K

Quest Diagnostics Inc.

DGXNYSEEQUITYCurrent

Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition On July 22, 2025, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Filed Jul 22, 2025Accepted Jul 22, 2025, 6:48 AM EDTCIK 1022079Accession 0001022079-25-000172
Share

Company context

Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We help connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, our insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three adult Americans each year, and our nearly 60,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www. QuestDiagnostics.com.

Current securities

Recent company filings

  1. 144 filingSep 1, 2026
  2. 4 filingAug 31, 2026
  3. 144 filingAug 28, 2026
  4. 144 filingJul 28, 2026
  5. 4 filingJul 27, 2026

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations
Item 2.02. Results of Operations and Financial Condition On July 22, 2025, Quest Diagnostics Incorporated (the "Company") issued a press release announcing, among other things, its results for the quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Filed exhibits (1)
EX-99.1 (by filename) dgx063020258-kex991.htm

EX-99.1 2 dgx063020258-kex991.htm EX-99.1 Document Exhibit 99.1 Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025 • Second quarter revenues of $2.76 billion, up 15.2% from 2024 • Second quarter reported diluted earnings per share ("EPS") of $2.47, up 21.7% from 2024; and adjusted diluted EPS of $2.62, up 11.5% from 2024 • Year-to-date cash provided by operations of $858 million, up 67.1% from 2024 • Full year 2025 reported diluted EPS now expected to be between $8.60 and $8.80; and adjusted diluted EPS is expected to be between $9.63 and $9.83 SECAUCUS, N.J., July 22, 2025 - Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the second quarter ended June 30, 2025. "Through continued execution of our strategy, we delivered a strong second quarter, with revenues growing 15.2% which includes 5.2% from organic revenues, as well as adjusted EPS growth of 11.5%," said Jim Davis, Chairman, CEO and President. "Demand for our innovative clinical solutions and expanded business from enterprise accounts complemented growth from acquisitions. We a…

Open exhibit ↗